Comparative Pharmacology
Head-to-head clinical analysis: CHOLINE C 11 versus MPI DMSA KIDNEY REAGENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLINE C 11 versus MPI DMSA KIDNEY REAGENT.
CHOLINE C-11 vs MPI DMSA KIDNEY REAGENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choline C-11 is a radioactive diagnostic agent; after intravenous administration, it is taken up by cells and phosphorylated by choline kinase. It accumulates in tissues with high choline metabolism, such as tumors (e.g., prostate cancer), allowing positron emission tomography (PET) imaging. The mechanism for tumor uptake is related to increased cell membrane synthesis and choline kinase activity.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
Intravenous: 370-740 MBq (10-20 mCi) as a single injection for PET imaging. Dose depends on patient weight, camera sensitivity, and imaging protocol.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
None Documented
None Documented
The terminal elimination half-life of [11C]choline in plasma is approximately 5-10 minutes. This short half-life is consistent with its use as a PET imaging agent, allowing same-day imaging without significant residual radiation exposure.
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Primarily renal excretion; approximately 70-80% of administered radioactivity is eliminated in urine within 2 hours, with less than 5% fecal elimination.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical